FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

WHO suspends Indian vax purchases as it probes quality

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools
  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

Perplexed by the appearance of mysterious white sediment inside vials of vaccine produced by an Indian subsidiary of Sanofi-Aventis, the World Health Organization has suspended the purchase and distribution of its Shan5 jab. According to Sanofi, the move comes as a "precautionary measure pending outcome of an investigation of vaccine quality."

A spokesperson for the WHO insists that there have been no safety problems yet discovered with the vaccine, a shot that provides protection against diphtheria, pertussis, tetanus, Haemophilus influenza B, and hepatitis B. However, even after vigorous shaking, the sediment was hard to disperse. And that, she adds, is a rare problem.

India's Shantha Biotechnics landed a contract valued at $340 million last fall to supply the vaccine to the WHO through 2012--just months after Sanofi bought it.

- here's the Wall Street Journal report

Related Articles:
Sanofi to donate 100M doses of new flu vaccine
Mass vaccination program could target schools


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Vaccine   Sanofi-Aventis   World Health Organization